Pembrolizumab Plus Chemotherapy in Patients With Advanced NSCLC Who Progressed on PD-1/PD-L1 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Cancer 2023 Jan 15;129(2)264-271, T Salous, NA Shukla, SK Althouse, SM Perkins, M Furqan, T Leal, AM Traynor, LE Feldman, NH Hanna, GA DurmFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.